Oragenics starts AG013 dosing in Phase II trial to treat oral mucositis

US-based antibiotics developer Oragenics has started dosing patients in a Phase II clinical trial of AG013 for the treatment of oral mucositis (OM).

Source: Drug Development Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news